Publications by authors named "Ida Paris"

Claim this Profile
L
Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer.
Alessandra Fabi, Antonio Franco, Laura Cortesi, Emanuela Lucci Cordisco, Alessandro Rossi, Ida Paris

JNCI Cancer Spectr· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study.
Guido Maria Giuffrè, Luisa Carbognin, Giovanna Masone Iacobucci, Maria Gistro, Antonio Tanzilli, Ida Paris

Breast Cancer Res Treat· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Federica Martorana, Maria V Sanò, Alessandra Fabi, Ida Paris, Vita Leonardi

Am J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report.
Federica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, Arianna Dri, Carmine Valenza, Ida Paris

Crit Rev Oncol Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study.
Giovanna Garufi, Luca Mastrantoni, Noemi Maliziola, Elena Di Monte, Giorgia Arcuri, Ida Paris

Clin Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.
Franco Antonio, Luisa Carbognin, Ida Paris, Alba Di Leone, Armando Orlandi

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review.
Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, Gianluigi Ferretti, Simona Gasparro, Ida Paris

Biol Direct· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria.
Charlotte Trombadori, Edda Boccia, Elena Huong Tran, Antonio Franco, Armando Orlandi, Ida Paris

Radiol Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors.
Flavia De Lauretis, Alejandro Martin Sanchez, Cristina Accetta, Beatrice Carnassale, Sabatino D'Archi, Ida Paris

Life (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters.
Silvia Taralli, Armando Orlandi, Pia Clara Pafundi, Valeria Tempesta, Alba Di Leone, Ida Paris

Radiol Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.
Luca Mastrantoni, Giovanna Garufi, Giulia Giordano, Noemi Maliziola, Elena Di Monte, Ida Paris

NPJ Breast Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.
Alessandra Fabi, Alessandro Rossi, Roberta Caputo, Simona Pisegna, Simone Scagnoli, Ida Paris

NPJ Precis Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.
Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, Francesca Sofia Di Lisa, Antonio Astone, Ida Paris

Cancers (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2.
Alessandra Fabi, Laura Cortesi, Simona Duranti, Emanuela Lucci Cordisco, Alba Di Leone, Ida Paris

Crit Rev Oncol Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Ida Paris

NPJ Breast Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Ida Paris

NPJ Breast Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients.
Elena Giordani, Matteo Allegretti, Alberto Sinibaldi, Francesco Michelotti, Gianluigi Ferretti, Ida Paris

J Exp Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Andrea Botticelli, Roberta Caputo, Simone Scagnoli, Simona Pisegna, Michelino De Laurentiis, Ida Paris

Oncologist· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients.
Alessandra Fabi, Alessandro Rossi, Edoardo Mocini, Ludovica Cardinali, Valerio Bonavolontà, Ida Paris

Curr Oncol Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis.
Roberta Caputo, Giuseppe Buono, Michela Piezzo, Claudia Martinelli, Daniela Cianniello, Ida Paris

Front Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital.
Inbal Dona Amar, Gianluca Franceschini, Camilla Nero, Ilaria Pasqua, Ida Paris

J Pers Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso

NPJ Breast Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions.
Daniele Generali, Rossana Berardi, Michele Caruso, Marina Cazzaniga, Ornella Garrone, Ida Paris

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aromatase inhibitors: the journey from the state of the art to clinical open questions.
Daniele Generali, Rossana Berardi, Michele Caruso, Marina Cazzaniga, Ornella Garrone, Ida Paris

Front Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
Marina Elena Cazzaniga, Antonio Ciaccio, Romano Danesi, Francois P Duhoux, Corrado Girmenia, Ida Paris

Front Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis